Psilocybin With Psychotherapy Shows Sustained Antidepressant Effects In New Study
Psilocybin therapy may not be only a short term intervention for depression. A new long term follow up study suggests that when psilocybin is paired with structured psychotherapy, some people with treatment resistant depression may continue to feel better for up to a year.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and  ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key takeaway | What it means |
|---|---|
| The study followed patients for 12 months | Researchers looked beyond the early weeks after treatment |
| Participants had treatment resistant depression | These were people who had not found enough relief from standard care |
| All participants received 25 mg of psilocybin | The treatment happened in a controlled clinical setting |
| Psychotherapy was part of the treatment | Preparation and integration sessions were included |
| Depression scores stayed lower on average | Symptoms remained meaningfully reduced at six and 12 months |
| The study still needs caution | The follow up period did not include a new control group |
New:Â Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Why The 12 Month Data Matters
Many psychedelic studies focus on rapid change. That makes sense. One of the most striking findings in this field has been how quickly some patients report relief after psilocybin assisted therapy.
But speed is only part of the story.
For depression, durability matters. A treatment that helps for days may feel promising. A treatment that helps for months raises a different clinical question.
In this study, researchers followed people from the EPIsoDE trial, which took place in Germany. Participants had received psilocybin with psychotherapeutic support. They were then assessed at six and 12 months.
On average, depressive symptoms remained lower throughout the follow up period. Even at 12 months, scores on a standard depression rating scale were about eight points lower than before treatment.
Psychotherapy Was Not A Side Detail
The study does not frame psilocybin as a stand alone pill. That distinction matters.
Participants received the psychedelic compound in a structured setting. The treatment included preparation before dosing and integration afterward. That gives patients a place to process the experience, rather than simply endure it or interpret it alone.
This is one reason psychedelic therapy differs from conventional daily antidepressants. Psilocybin is not taken every morning. It is used in a small number of sessions, with clinical support around it.
That model may be part of its appeal. It may also be part of its complexity.
The Caution Is Important
The findings are encouraging, but they do not settle the question.
This was a naturalistic follow up, not a new placebo controlled trial across the full 12 month period. After the main study ended, participants could resume usual treatments. Some also joined a monthly integration group.
Those details make the results harder to interpret. The improvement may reflect psilocybin, psychotherapy, later treatment, ongoing support, or some combination of these factors.
Still, the study adds weight to a central question in psychedelic medicine. Can a brief, supported intervention create changes that last?
For people living with treatment resistant depression, that question is not abstract. It is the difference between temporary relief and a wider path forward.
